Found: 24
Select item for more details and to access through your institution.
Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.
- Published in:
- Scientific Reports, 2013, p. 1, doi. 10.1038/srep03494
- By:
- Publication type:
- Article
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-37883-y
- By:
- Publication type:
- Article
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
- Published in:
- NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00273-9
- By:
- Publication type:
- Article
Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF<sup>V600</sup> melanoma cells.
- Published in:
- Scientific Data, 2020, v. 7, n. 1, p. N.PAG, doi. 10.1038/s41597-020-00683-z
- By:
- Publication type:
- Article
The therapeutic potential of targeting minimal residual disease in melanoma.
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 3, p. 1, doi. 10.1002/ctm2.1197
- By:
- Publication type:
- Article
PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
- Published in:
- PLoS ONE, 2023, v. 18, n. 11, p. 1, doi. 10.1371/journal.pone.0292278
- By:
- Publication type:
- Article
Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers.
- Published in:
- PLoS ONE, 2011, v. 6, n. 4, p. 1, doi. 10.1371/journal.pone.0018064
- By:
- Publication type:
- Article
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-28705-x
- By:
- Publication type:
- Article
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
- Published in:
- Pigment Cell & Melanoma Research, 2014, v. 27, n. 4, p. 590, doi. 10.1111/pcmr.12228
- By:
- Publication type:
- Article
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
- Published in:
- Journal of Clinical Investigation, 2012, v. 122, n. 2, p. 553, doi. 10.1172/JCI59309
- By:
- Publication type:
- Article
Cyclosporin A and FK506 are Potent Activators of Proopiomelanocortin-Derived Peptide Secretion Without Affecting Corticotrope Glucocorticoid Receptor Function.
- Published in:
- Journal of Neuroendocrinology, 1995, v. 7, n. 11, p. 833, doi. 10.1111/j.1365-2826.1995.tb00723.x
- By:
- Publication type:
- Article
Glucocorticoid Receptor Function in Rat Pituitary Intermediate Lobe is Inhibited by an Endogenous Protein.
- Published in:
- Journal of Neuroendocrinology, 1993, v. 5, n. 2, p. 195, doi. 10.1111/j.1365-2826.1993.tb00381.x
- By:
- Publication type:
- Article
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
- Published in:
- Science Signaling, 2015, v. 8, n. 390, p. 1, doi. 10.1126/scisignal.aab1111
- By:
- Publication type:
- Article
AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer.
- Published in:
- Science Signaling, 2011, v. 4, n. 188, p. 1, doi. 10.1126/scisignal.2001754
- By:
- Publication type:
- Article
Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6342, doi. 10.3390/cancers13246342
- By:
- Publication type:
- Article
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies.
- Published in:
- Cancers, 2021, v. 13, n. 22, p. 5810, doi. 10.3390/cancers13225810
- By:
- Publication type:
- Article
PRMT5: An Emerging Target for Pancreatic Adenocarcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 20, p. 5136, doi. 10.3390/cancers13205136
- By:
- Publication type:
- Article
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF V600 Melanoma via a p53 Dependent Pathway.
- Published in:
- Cancers, 2021, v. 13, n. 3, p. 524, doi. 10.3390/cancers13030524
- By:
- Publication type:
- Article
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1583, doi. 10.3390/cancers12061583
- By:
- Publication type:
- Article
Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1
- Published in:
- Cardiovascular Research, 2006, v. 70, n. 3, p. 555, doi. 10.1016/j.cardiores.2006.02.010
- By:
- Publication type:
- Article
AKT-independent PI3-K signaling in cancer -emerging role for SGK3.
- Published in:
- Cancer Management & Research, 2013, v. 5, p. 281, doi. 10.2147/CMAR.S35178
- By:
- Publication type:
- Article
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. N.PAG, doi. 10.3389/fimmu.2021.661737
- By:
- Publication type:
- Article
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
- Published in:
- International Journal of Cancer, 2018, v. 142, n. 10, p. 2139, doi. 10.1002/ijc.31220
- By:
- Publication type:
- Article